1. Home
  2. MSDL vs CRNX Comparison

MSDL vs CRNX Comparison

Compare MSDL & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • CRNX
  • Stock Information
  • Founded
  • MSDL 2019
  • CRNX 2008
  • Country
  • MSDL United States
  • CRNX United States
  • Employees
  • MSDL N/A
  • CRNX N/A
  • Industry
  • MSDL
  • CRNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSDL
  • CRNX Health Care
  • Exchange
  • MSDL NYSE
  • CRNX Nasdaq
  • Market Cap
  • MSDL 1.7B
  • CRNX 2.8B
  • IPO Year
  • MSDL N/A
  • CRNX 2018
  • Fundamental
  • Price
  • MSDL $19.25
  • CRNX $31.75
  • Analyst Decision
  • MSDL Hold
  • CRNX Strong Buy
  • Analyst Count
  • MSDL 5
  • CRNX 8
  • Target Price
  • MSDL $20.00
  • CRNX $74.86
  • AVG Volume (30 Days)
  • MSDL 423.2K
  • CRNX 751.6K
  • Earning Date
  • MSDL 01-01-0001
  • CRNX 08-07-2025
  • Dividend Yield
  • MSDL 11.46%
  • CRNX N/A
  • EPS Growth
  • MSDL N/A
  • CRNX N/A
  • EPS
  • MSDL N/A
  • CRNX N/A
  • Revenue
  • MSDL N/A
  • CRNX $760,000.00
  • Revenue This Year
  • MSDL $1,597.39
  • CRNX $402.02
  • Revenue Next Year
  • MSDL $15.10
  • CRNX $771.03
  • P/E Ratio
  • MSDL N/A
  • CRNX N/A
  • Revenue Growth
  • MSDL N/A
  • CRNX N/A
  • 52 Week Low
  • MSDL $17.59
  • CRNX $24.10
  • 52 Week High
  • MSDL $23.63
  • CRNX $62.53
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 50.38
  • CRNX 57.94
  • Support Level
  • MSDL $18.84
  • CRNX $28.98
  • Resistance Level
  • MSDL $19.19
  • CRNX $32.49
  • Average True Range (ATR)
  • MSDL 0.28
  • CRNX 1.24
  • MACD
  • MSDL 0.02
  • CRNX 0.30
  • Stochastic Oscillator
  • MSDL 75.95
  • CRNX 90.54

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Share on Social Networks: